More Than Pathogen Reduction: Seraph 100 In COVID-19 Patients

EXTHERA

ExThera Medical was formed in 2007 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB, at the Karolinska Institute of Stockholm. We are focused on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations, with field deployable versions for biodefense and military.

The company’s first product, the Seraph® 100 Microbind® Affinity Blood Filter, is CE Marked for the reduction of pathogens during bloodstream infections in adjunction to antibiotics and commercially available in Europe.

Registration available online here